Cosentyx is the only IL-17A inhibitor approved for this population, and the first differentiated mechanism in nearly a ...

Cosentyx is the only IL-17A inhibitor approved for this population, and the first differentiated mechanism in nearly a decade1-3 HS often emerges around puberty, underscoring importance of early diagn ...

Regulatory clearance positions secukinumab as the sole IL‑17A–targeting option for pediatric HS, expanding therapeutic choice beyond historically limited adolescent interventions. IL‑17A blockade is ...

UCB said it’s the first time an approved biologic demonstrated superiority over an IL-23 blocker in psoriatic arthritis. Yet analysts aren’t sure how commercially impactful the results will be.